×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PTGX – protagonist therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PTGX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/7
09:28 pm
ptgx
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
1/7
06:21 pm
ptgx
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
Medium
Report
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
1/5
09:10 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.
1/5
07:40 am
ptgx
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]
Low
Report
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]
12/25
04:12 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
12/17
07:19 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/8
07:22 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/5
04:43 pm
ptgx
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
ptgx
protagonist therapeutics, inc.
MISS
Report
-0.3%
protagonist therapeutics, inc.
8/6/2025
04:05 pm
ptgx
protagonist therapeutics, inc.
MISS
Report
-5.4%
protagonist therapeutics, inc.
5/6/2025
04:05 pm
ptgx
protagonist therapeutics, inc.
BEAT
Report
2.6%
protagonist therapeutics, inc.
2/21/2025
07:00 am
ptgx
protagonist therapeutics, inc.
BEAT
Report
-0.8%
protagonist therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/13
04:45 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 09 Filed by: SELICK HAROLD E
Medium
Report
Form 4 Protagonist Therapeutics For: Jan 09 Filed by: SELICK HAROLD E
1/12
08:01 am
ptgx
Form 8-K Protagonist Therapeutics For: Jan 12
Low
Report
Form 8-K Protagonist Therapeutics For: Jan 12
1/6
07:44 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: SELICK HAROLD E
Low
Report
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: SELICK HAROLD E
1/6
07:43 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: Waddill William D.
Low
Report
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: Waddill William D.
1/6
07:42 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: Giraudo Bryan
Low
Report
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: Giraudo Bryan
1/6
07:41 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: Williams Lewis T
Low
Report
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: Williams Lewis T
1/6
07:39 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: O'Dowd Sarah A
Low
Report
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: O'Dowd Sarah A
1/6
07:38 pm
ptgx
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: PATEL DINESH V PH D
Low
Report
Form 4 Protagonist Therapeutics For: Jan 02 Filed by: PATEL DINESH V PH D
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/3
Form 4 Protagonist Therapeutics For: Dec 03 Filed by: PATEL DINESH V PH D
70.0%
3/12 Form 4 Protagonist Therapeutics For: Mar 12 Filed by: SELICK HAROLD E 18.3%
5/8 Form 10-Q Protagonist Therapeutics For: Mar 31 16.7%
3/18 Form 8-K Protagonist Therapeutics For: Mar 13 10.9%
10/30 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera 8.1%
8/17 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.8%
9/25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 7.1%
8/20 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.6%
5/8 Q1/2019 3/31/2019 EPS -0.580 ZacksConsensus -0.640 ActVsEst 0.060 - Beat 6.2%
11/9 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.3%
3/12 Form 4 Protagonist Therapeutics For: Mar 12 Filed by: SELICK HAROLD E 18.3%
5/8 Form 10-Q Protagonist Therapeutics For: Mar 31 16.7%
3/18 Form 8-K Protagonist Therapeutics For: Mar 13 10.9%
10/30 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera 8.1%
8/17 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.8%
9/25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 7.1%
8/20 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.6%
5/8 Q1/2019 3/31/2019 EPS -0.580 ZacksConsensus -0.640 ActVsEst 0.060 - Beat 6.2%
11/9 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.3%
TOP News Decliners
12/3
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
-46.7%
11/6 Form 10-Q Protagonist Therapeutics For: Sep 30 -14.4%
11/25 Form EFFECT Protagonist Therapeutics -11.9%
5/7 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 -11.1%
11/26 Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug [Seeking Alpha] -7.7%
3/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.3%
3/12 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 price target on the stock. -6.7%
3/10 Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
11/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.8%
7/25 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.7%
11/6 Form 10-Q Protagonist Therapeutics For: Sep 30 -14.4%
11/25 Form EFFECT Protagonist Therapeutics -11.9%
5/7 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 -11.1%
11/26 Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug [Seeking Alpha] -7.7%
3/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.3%
3/12 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 price target on the stock. -6.7%
3/10 Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
11/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.8%
7/25 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: